Claim Construction at the UPC: A Review of EPO, National and UPC Case Law This session examines the UPC’s evolving approach to claim interpretation, highlighting key decisions that clarify how claims are construed in comparison with EPO and national practices. It will explore recent landmark rulings and ongoing developments shaping patent litigation strategies.

• Review the UPC Court of Appeal decision NanoString Technologies v. 10xGenomics, which clarified the standard for interpreting patent claims based on Article 69 EPC and its Protocol, affecting both infringement and validity assessments.
• Examine the ongoing question of whether the file wrapper should be considered in claim construction, which awaits a final decision by the UPC Court of Appeal.
• Analyse the decision of G1/24 and its impact upon claims raised at national courts, the EPO and the UPC.

1) Technology Development-  Dos/Don’ts

2 ) Commercialization Dos/ Don’ts

3)  Reimbursement  strategy Dos/Don’ts

4)  Funding a Scalable business

• Shifting from delayed diagnosis to early detection by using advances in biomarkers, imaging, and AI to shorten the average 7–10 year diagnostic journey and reduce patient suffering and improving pelvic health.
• Expanding treatment options beyond surgery and hormones with next-generation therapeutics, digital therapeutics, and integrative care models to manage symptoms and improve quality of life.
• Centering the patient in holistic care models by redesigning care pathways to address pain, fertility, mental health, and workplace impact with multidisciplinary and patient-driven approaches